Ask The Board

  1. In September, You Testified Before Congress On The Inflation Reduction Act's (IRA) Real-World Impact On Rare Disease R&D And Small Molecule Therapies. Can You Summarize The Key Points? 11/1/2023

    See the answer from John Crowley, chairman and CEO at Amicus Therapeutics.

  2. What New Technologies Offer The Most Promise For Improving Global Supply Chain Operations? 11/1/2023

    See the answer from Anu Hans, VP, strategic initiatives at Johnson & Johnson Innovative Medicine.

  3. Given Drug Development Time Horizons, How Does A Company Best Navigate The Inevitable Vagaries Of Investor Therapeutic/Modality Sentiment And Its Collateral Consequences On Funding? 10/2/2023

    See the answer from Allan Shaw, an independent consultant and chief financial officer at Portage Biotech.

  4. How Can Leaders Balance Requests Of Employees To Continue Remote Working With The Need For Increased Business Efficiency And Achieving Strong Dynamics Among A Management Team? 10/2/2023

    See the answer from David Pyott, chairman at London Business School, a board member at Alnylam Therapeutics, and the former chairman and CEO of Allergan.

  5. What Impact Is The Inflation Reduction Act Already Having On Biopharma Companies, And What More Can The Industry Do Going Forward? 9/1/2023

    See the answer from Stephen Rapundalo, president and CEO of MichBio.

  6. How Can Executives Work Through Tightened Budgets And Manage Tradeoffs While Keeping The Workforce Happy And Motivated? 9/1/2023

    See the answer from Tim Wright, chairman of the board of directors at Isosceles Pharmaceuticals.

  7. How Can Drug Developers Work Together With The FDA To Maximize The Value Of A Clinical Trial Protocol? 8/1/2023

    See the answer from Mitchell Katz, PhD, SVP, global clinical operations, at Kyowa Kirin.

  8. In These Times Of Increasingly Unpredictable And Lurching Change, What Skills Will Separate Out Next-Gen CEOs? 8/1/2023

    See the answer from Fred Hassan, the managing director at Warburg Pincus.

  9. In Partnering With Academic Institutions To Advance Drug Discovery, What Are The Key Benefits And Challenges? 6/1/2023

    See the answer from Chandra Ramanathan, global head, innovation hubs, at Danaher Corporation.

  10. In Discussing A Strategic Initiative Presented To The Board By Management, Such As A Bolt-On Acquisition, What Are The Three Core Questions That Boards Should Always Ask? 6/1/2023

    See the answer from Fred Hassan, managing director at Warburg Pincus.